Filing Details

Accession Number:
0001144204-11-028443
Form Type:
4
Zero Holdings:
No
Publication Time:
2011-05-12 12:04:26
Reporting Period:
2011-05-10
Filing Date:
2011-05-12
Accepted Time:
2011-05-12 12:04:26
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1077183 Neogenomics Inc NGNM.OB Services-Testing Laboratories (8734) 742897368
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1518733 M Douglas Oort Van C/O Neogenomics, Inc.
12701 Commonwealth Drive Suite 9
Fort Myers FL US 33913
Chairman And Ceo Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2011-05-10 600 $1.40 787,890 No 4 P Indirect Trust by Self
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect Trust by Self
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 8,600 Direct
Reported Derivative Holdings
Sec. Name Sec. Type Price Date Expiration Date Amount Remaning Holdings Nature of Ownership
Common Stock Stock option (right to buy) $0.80 2009-12-31 2016-03-15 0 1,000,000 Direct
Common Stock Warrant (right to buy) $1.05 2009-03-16 2014-03-15 0 625,000 Direct
Expiration Date Amount Remaning Holdings Nature of Ownership
2016-03-15 0 1,000,000 Direct
2014-03-15 0 625,000 Direct
Footnotes
  1. On March 15, 2009 Mr. VanOort was granted options to purchase 1,000,000 shares. The grant was comprised of 500,000 time based options and 500,000 performance based options. The first date of vesting when an option became exercisable was December 31, 2009 when 200,000 performance based options vested. Mr. VanOort will have 374,000 time based options vested and exercisable within 60 days of this filing. There are 300,000 performance based options which are not vested or exercisable.
  2. On March 16, 2009 Mr. VanOort was granted a warrant to purchase 625,000 shares. Of this total 125,000 warrants were immediately exercisable and vested. The remaining 500,000 warrants vest based on performance of the Company stock price and are not exercisable or vested at the present time.